Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Phys Chem B ; 128(26): 6338-6351, 2024 Jul 04.
Artigo em Inglês | MEDLINE | ID: mdl-38903016

RESUMO

Ceramide transfer protein CERT is the mediator of nonvesicular transfer of ceramide from the ER to Golgi. In CERT, START is the domain responsible for the binding and transport of ceramide. A wealth of structural data has revealed a helix-grip fold surrounding a large hydrophobic cavity holding the ceramide. Yet, little is known about the mechanisms by which START releases the ceramide through the polar region and into the packed environment of cellular membranes. As such events do not lend themselves easily to experimental investigations, we used multiple unbiased microsecond-long molecular simulations. We propose a membrane-assisted mechanism in which the membrane acts as an allosteric effector initiating the release of ceramide and where the passage of the ceramide acyl chains is facilitated by the intercalation of a single phosphatidylcholine lipid in the cavity, practically greasing the ceramide way out. We verify using free energy calculation and experimental lipidomics data that CERT forms stable complexes with phosphatidylcholine lipids, in addition to ceramide, thus providing validation for the proposed mechanism.


Assuntos
Ceramidas , Simulação de Dinâmica Molecular , Ceramidas/química , Fosfatidilcolinas/química , Humanos , Domínios Proteicos , Termodinâmica , Membrana Celular/química , Membrana Celular/metabolismo , Proteínas Serina-Treonina Quinases
2.
J Chem Inf Model ; 64(3): 621-626, 2024 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-38276895

RESUMO

Using a combination of multisite λ-dynamics (MSλD) together with in vitro IC50 assays, we evaluated the polypharmacological potential of a scaffold currently in clinical trials for inhibition of human neutrophil elastase (HNE), targeting cardiopulmonary disease, for efficacious inhibition of Proteinase 3 (PR3), a related neutrophil serine proteinase. The affinities we observe suggest that the dihydropyrimidinone scaffold can serve as a suitable starting point for the establishment of polypharmacologically targeting both enzymes and enhancing the potential for treatments addressing diseases like chronic obstructive pulmonary disease.


Assuntos
Polifarmacologia , Humanos , Mieloblastina , Proteínas Secretadas Inibidoras de Proteinases
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA